Lyell Immunopharma, Inc.
LYEL · XNASCIK 1806952fmd_0QBDD5F7KEQN5619GJSXJ3EHCRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 27 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 8 | 11 | 85 | 0 | 0 | 0 |
| Research and development | 64 | 182 | 139 | 159 | 183 | 172 | 159 |
| Total operating expenses | 103 | 220 | 225 | 272 | 247 | 359 | 269 |
| Operating income | (102) | (212) | (215) | (187) | (247) | (359) | (269) |
| Other non-operating income (expense) | (27) | 7 | (35) | 4 | 12 | 16 | (5) |
| Income tax expense | – | – | – | – | – | – | 0 |
| Net income | (129) | (204) | (250) | (183) | (235) | (343) | (274) |
| Net income to common shareholders | (131) | (208) | (250) | (183) | – | – | – |